NCT02234843 (EINSTEIN Jr) is a Phase 3 clinical trial of Rivaroxaban (Xarelto, BAY59-7939) in Venous Thromboembolism, sponsored by Bayer.

Who is sponsoring NCT02234843?

NCT02234843 is sponsored by Bayer.

What drugs are being tested in NCT02234843?

Interventions in NCT02234843: Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban (Xarelto, BAY59-7939), Standard of Care.

What condition does NCT02234843 study?

NCT02234843 studies Venous Thromboembolism.

Is NCT02234843 still recruiting?

NCT02234843 is currently completed. Last updated 1 April 2020.

Are results published for NCT02234843?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-04-01 · How we verify

NCT02234843: EINSTEIN Jr

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

Completed Phase 3 Results posted Last updated 1 April 2020

What this trial tests

Phase 3 trial testing Rivaroxaban (Xarelto, BAY59-7939) in Venous Thromboembolism in 500 participants. Completed in 30 January 2019.

Timeline

13 November 2014

Primary endpoint
30 January 2019

30 January 2019

Quick facts

Lead sponsor	Bayer
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	500
Start date	13 November 2014
Primary completion	30 January 2019
Estimated completion	30 January 2019
Sites	109 locations across Belgium, Russia, Finland, Ireland, United States, Hungary, Mexico, Germany

Drugs / interventions tested

Rivaroxaban (Xarelto, BAY59-7939) — full drug profile →
Rivaroxaban (Xarelto, BAY59-7939) — full drug profile →
Standard of Care

Conditions studied

Venous Thromboembolism — all drugs for Venous Thromboembolism →

Sponsor

Bayer — full company profile →

Who can join

Under 17, any sex, with Venous Thromboembolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
Male C, Lensing AWA, Palumbo JS, Kumar R, et al · · 2020 · cited 209× · PMID 31699660 · DOI 10.1016/s2352-3026(19)30219-4
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT).
Connor P, Sánchez van Kammen M, Lensing AWA, Chalmers E, et al · · 2020 · cited 78× · PMID 33351120 · DOI 10.1182/bloodadvances.2020003244
Management of thrombosis in children and neonates: practical use of anticoagulants in children.
Monagle P, Newall F. · · 2018 · cited 63× · PMID 30504338 · DOI 10.1182/asheducation-2018.1.399
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
Monagle P, Lensing AWA, Thelen K, Martinelli I, et al · · 2019 · cited 52× · PMID 31420317 · DOI 10.1016/s2352-3026(19)30161-9
Role of direct oral anticoagulants in patients with kidney disease.
Derebail VK, Rheault MN, Kerlin BA. · · 2020 · cited 38× · PMID 32107019 · DOI 10.1016/j.kint.2019.11.027
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE).
Thom K, Lensing AWA, Nurmeev I, Bajolle F, et al · · 2020 · cited 37× · PMID 33002131 · DOI 10.1182/bloodadvances.2020002637
Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review.
Bose G, Graveline J, Yogendrakumar V, Shorr R, et al · · 2021 · cited 30× · PMID 33593766 · DOI 10.1136/bmjopen-2020-040212
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study.
Lensing AWA, Male C, Young G, Kubitza D, et al · · 2018 · cited 30× · PMID 30598642 · DOI 10.1186/s12959-018-0188-y

Verify or expand the search:

Other trials of Rivaroxaban (Xarelto, BAY59-7939)

Trials testing the same drug.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT06193863 — An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Hea · active not recruiting
NCT05461807 — An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to · completed
NCT05150938 — A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE) · completed
NCT04923139 — A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Datab · completed

Other recruiting trials for Venous Thromboembolism

Currently open trials in the same condition.

NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02234843 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 1 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02234843.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing